ESHAP therapy effective in a patient with Langerhans cell sarcoma

Area of Science:

• Oncology
• Hematology
• Transplantation Medicine

Background:

• Langerhans cell sarcoma (LCS) is a rare malignancy with systemic involvement.
• Liver transplantation presents unique challenges in managing subsequent oncological emergencies.
• Chemotherapy selection requires careful consideration in post-transplant patients.

Observation:

• A 53-year-old woman with systemic LCS post-liver transplant initially responded to CHOP chemotherapy.
• Disease progression occurred despite first-line treatment, necessitating intensive care for systemic LCS and infections.
• A modified ESHAP regimen was initiated as second-line therapy.

Findings:

• The modified ESHAP regimen (etoposide, carboplatin, cytarabine, methylprednisolone) demonstrated a marked response in treating systemic LCS.
• Four cycles of modified ESHAP led to significant clinical improvement.
• This regimen proved effective in a complex post-transplant setting.

Implications:

• Modified ESHAP chemotherapy is a potentially highly effective treatment for Langerhans cell sarcoma.
• This regimen may offer a viable therapeutic option for patients with advanced or refractory LCS.
• Further research into modified ESHAP for LCS, particularly in immunocompromised patients, is warranted.